Article
Holland, V. A.; Winborn, K.; Thompson, M.; Rami, H. K.;
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 8 3347
D.; Blum, C. A. From arylureas to biarylamides to aminoquinazo-
lines: discovery of a novel, potent TRPV1 (VR1) antagonist. Bioorg.
Med. Chem. Lett. 2006, 16, 5217–5221.
Randall, A. D.; Davis, J. B. Characterization of SB-705498, a
potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist
that inhibits the capsaicin-, acid-, and heat-activation of the
receptor. J. Pharmacol. Exp. Ther. 2007, 321, 1183–1192.
(19) (a) DeSimone, R.W.;Hodgetts, K.;Krause, J. E.;White,G. PCTWO
02/08221, 2002. (b) Bakthavatchalam, R.; Hutchison, A.; DeSimone,
R. W.; Hodgetts, K.; Krause, J. E.; White, G. U.S. Patent 6,723,730, 2004.
(20) Other groups reporting on the arylurea series: (a) Sun, Q.; Tafesse,
L.; Islam, K.; Zhou, X.; Victory, S. F.; Zhang, C.; Hachicha, M.;
Schmid, L. A.; Patel, A.; Rotshteyn, Y.; Valenzano, K. J.; Kyle,
D. J. 4-(2-Pyridyl)piperazine-1-carboxamides: potent vanilloid
receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 3611–
3616. (b) Tafesse, L.; Sun, Q.; Schmid, L. A.; Valenzano, K. J.;
Rotshteyn, Y.; Su, X.; Kyle, D. J. Synthesis and evaluation of pyrida-
zinylpiperazines as vanilloid receptor 1 antagonists. Bioorg. Med.
Chem. Lett. 2004, 14, 5513–5519. (c) Swanson, D. M.; Dubin,
A. E.; Shah, C.; Nasser, N.; Chang, L.; Dax, S. L.; Jetter, M.;
Breitenbrucher, J. G.; Codd, E. E.; Lee, D. H.; Zhang, S.-P.; Chaplan,
S. R.; Carruthers, N. I. Identification and biological evaluation of 4-(3-
trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoro-
methylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid
receptor antagonist. J. Med. Chem. 2005, 48, 1857–1872. (d) Pomonis,
J. D.; Harrison, J. E.; Lilly, M.; Bristol, D. R.; Valenzano, K. J.; Walker,
K. N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyr-
azine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid
receptor 1 antagonist with analgesic properties: II. In vivo characteriza-
tion in rat models of inflammatory and neuropathic pain. J. Pharmacol.
Exp. Ther. 2003, 306, 387–393. (e) Valenzano, K. J.; Grant, E. R.; Wu,
G.; Hachicha, M.; Schmid, L.; Tafesse, L.; Sun, Q.; Rotshteyn, Y.;
Francis, J.; Limberis, J.; Malik, S.; Whittemore, E. R.; Hodges, D. N-(4-
Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-
carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1
antagonist with analgesic properties: I. In vitro characterization
and pharmacokinetic properties. J. Pharmacol. Exp. Ther. 2003,
306, 377–386.
(12) (a) Rami, H. K.; Thompson, M.; Wyman, P.; Jerman, J. C.;
Egerton, J.; Brough, S.; Stevens, A. J.; Randall, A. D.; Smart,
D.; Gunthorpe, M. J.; Davis, J. B. Discovery of small molecule
antagonists of TRPV1. Bioorg. Med. Chem. Lett. 2004, 14, 3631–
3634. (b) Rami, H. K.; Thompson, M.; Stemp, G.; Fell, S.; Jerman, J. C.;
Stevens, A. J.; Smart, D.; Sargent, B.; Sanderson, D.; Randall, A. D.;
Gunthorpe, M. J.; Davis, J. B. Discovery of SB-705498: a potent,
selective and orally bioavailable TRPV1 antagonist suitable for clinical
development. Bioorg. Med. Chem. Lett. 2006, 16, 3287–3291.
(13) Chizh, B. A.; O’Donnell, M. B.; Napolitano, A.; Wang, J.; Brooke,
A. C.; Aylott, M. C.; Bullman, J. N.; Gray, E. J.; Lai, R. Y.;
Williams, P. M.; Appleby, J. M. The effects of the TRPV1
antagonist SB-705498 on TRPV1 receptor-mediated activity and
inflammatory hyperalgesia in humans. Pain 2007, 132, 132–141.
(14) (a) Doherty, E. M.; Fotsch, C.; Bo, Y.; Chakrabarti, P. P.; Chen,
N.; Gavva, N.; Han, N.; Kelly, M. G.; Kincaid, J.; Klionsky, L.;
Liu, Q.; Ognyanov, V. I.; Tamir, R.; Wang, X.; Zhu, J.; Norman,
M. H.; Treanor, J. J. S. Discovery of potent, orally available
vanilloid receptor-1 antagonists. Structure-activity relationship
of N-aryl cinnamides. J. Med. Chem. 2005, 48, 71–90. (b) Norman,
M. H.; Zhu, J.; Fotsch, C.; Bo, Y.; Chen, N.; Chakrabarti, P.; Doherty,
E. M.; Gavva, N. R.; Nishimura, N.; Nixey, T.; Ognyanov, V. I.; Rzasa,
R. M.; Stec, M.; Surapaneni, S.; Tamir, R.; Viswanadhan, V. N.;
Treanor, J. J. Novel vanilloid receptor-1 antagonists: 1. Conformation-
ally restricted analogues. J. Med. Chem. 2007, 50, 3497–3514.
(c) Doherty, E. M.; Fotsch, C.; Bannon, A. W.; Bo, Y.; Chen, N.;
Dominguez, C.; Falsey, J.; Gavva, N. R.; Katon, J.; Nixey, T.;
Ognyanov, V. I.; Pettus, L.; Rzasa, R. M.; Stec, M.; Surapaneni, S.;
Tamir, R.; Zhu, J.; Treanor, J. J.; Norman, M. H. Novel vanilloid
receptor-1 antagonists: 2. Structure-activity relationships of 4-oxo-
pyrimidines leading to the selection of a clinical candidate. J. Med.
Chem. 2007, 50, 3415–3527. (d) Wang, H.-L.; Katon, J.; Balan, C.;
Bannon, A. W.; Bernard, C.; Doherty, E. M.; Dominguez, C.; Gavva, N.
R.; Gore, V.; Ma, V.; Nishimura, N.; Surapaneni, S.; Tang, P.; Tamir, R.;
Thiel, O.; Treanor, J. J.; Norman, M. H. Novel vanilloid receptor-1
antagonists: 3. Identification of a second-generation clinical candidate
with improved physicochemical and pharmacokinetic properties.
J. Med. Chem. 2007, 50, 3428–3539.
(21) Blum, C. A.; Zheng, X.; Brielmann, H.; Hodgetts, K. J.;
Bakthavatchalam, R.; Chandrasekhar, J.; Krause, J. K.; Cortright,
D.; Matson, D.; Crandall, M.; Ngo, C. K.; Fung, L.; Day, M.;
Kershaw, M.; De Lombaert, S.; Chenard, B. L. Aminoquinazolines
as TRPV1 antagonists: modulation of drug-like properties through
the exploration of 2-position substitution. Bioorg. Med. Chem.
Lett. 2008, 18, 4573.
(22) As assessed by percentage of block of hERG potassium channels
using an in vitro electrophysiological whole cell (Cos7) assay at a
compound concentration of 3 μM.
(15) Gavva, N. R.; Treanor, J. J. S.; Garami, A.; Fang, L.; Surapaneni,
S.; Akrami, A.; Alvarez, F.; Bak, A.; Darling, M.; Gore, A.; Jang,
G. R.; Kesslak, J. P.; Ni, L.; Norman, M. H.; Palluconi, G.; Rose,
M. J.; Salfi, M.; Tan, E.; Romanovsky, A. A.; Banfield, C.; Davar,
G. Pharmacological blockade of the vanilloid receptor TRPV1
elicits marked hyperthermia in humans. Pain 2008, 136, 202–210.
(16) (a) Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Zheng, G. Z.;
Perner, R. J.; Didomenico, S.; Koenig, J. R.; Turner, S.; Jinkerson,
T.; Drizin, I.; Hannick, S. M.; Macri, B. S.; McDonald, H. A.;
Honore, P.; Wismer, C. T.; Marsh, K. C.; Wetter, J.; Stewart,
K. D.; Oie, T.; Jarvis, M. F.; Surowy, C. S.; Faltynek, C. R.; Lee,
C.-H. Novel transient receptor potential vanilloid 1 receptor
antagonists for the treatment of pain: Structure-activity relation-
ships for ureas with quinoline, isoquinoline, quinazoline, phthala-
zine, quinoxaline, and cinnoline moieties. J. Med. Chem. 2005, 48,
744–752. (b) Gomtsyan, A.; Bayburt, E. K.; Keddy, R.; Turner, S. C.;
Jinkerson, T. K.; DiDomenico, S.; Perner, R. J.; Koenig, J. R.; Drizin, I.;
McDonald, H. A.; Surowy, C. S.; Honore, P.; Mikusa, J.; Marsh, K. C.;
Wetter, J. M.; Faltynek, C. R.; Lee, C.-H. R-Methylation at benzylic
fragment of N-aryl-N0-benzyl ureas provides TRPV1 antagonists with
better pharmacokinetic properties and higher efficacy in inflamma-
tory pain model. Bioorg. Med. Chem. Lett. 2007, 17, 3894–3899.
(c) Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Surowy, C. S.;
Honore, P.; Marsh, K. C.; Hannick, S. M.; McDonald, H. A.; Wetter,
J. M.; Sullivan, J. P.; Jarvis, M. F.; Faltynek, C. R.; Lee, C. H.
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-
3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for
pain management. J. Med. Chem. 2008, 51, 392–395.
(23) Brent, R. L. Teratogen update: reproductive risks of leflunomide
(Arava); a pyrimidine synthesis inhibitor: counseling women tak-
ing leflunomide before or during pregnancy and men taking
leflunomide who are contemplating fathering a child. Teratology
2001, 63, 106–112.
(24) Rewcastle, G. W.; Denny, W. A.; Showalter, H. D. H. Synthesis of
4-(phenylamino)pyrimidine derivatives as ATP-competitive pro-
tein kinase inhibitors with potential for cancer chemotherapy.
Curr. Org. Chem. 2000, 4, 679–706.
(25) Maligres, P. E.; Waters, M. S.; Fleitz, F.; Askin, D. A highly
catalytic robust palladium catalyzed cyanation of aryl bromides.
Tetrahedron Lett. 1999, 40, 8193–8195.
(26) Yin, J.; Zhao, M. M.; Huffman, M. A.; McNamara, J. M.
Pd-Catalyzed N-arylation of heteroarylamines. Org. Lett. 2002,
4, 3481–3484.
(27) Cai, S. X.; Zhou, Z.-L.; Huang, J.-C.; Whittemore, E. R.;
€
Egbuwoku, Z. O.; Lu, Y.; Hawkinson, J. E.; Woodward, R. M.;
Weber, E.; Keana, J. F. W. Synthesis and structure-activity
relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes:
novel and highly potent antagonists for NMDA receptor glycine
site. J. Med. Chem. 1996, 39, 3248–3255.
(28) (a) Ram, S.; Ehrenkaufer, R. E. Ammonium formate in organic
synthesis: a versatile agent in catalytic hydrogen transfer reduc-
tions. Synthesis 1988, 91–95. (b) Anwer, M. K.; Sherman, D. B.;
Roney, J. G.; Spatola, A. F. Applications of ammonium formate
catalytic transfer hydrogenation. 6. Analysis of catalyst, donor quantity,
and solvent effects upon the efficacy of dechlorination. J. Org. Chem.
1989, 54, 1284–1289.
(17) Surowy, C. S.; Neelands, T. R.; Bianchi, B. R.; McGaraughty, S.;
El Kouhen, R.; Han, P.; Chu, K. L.; McDonald, H. A.; Vos, M.;
Niforatos, W.; Bayburt, E. K.; Gomtsyan, A.; Lee, C. H.; Honore,
P.; Sullivan, J. P.; Jarvis, M. F.; Faltynek, C. R. ABT-102 ((R)-
(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea)
blocks polymodal activation of TRPV1 receptors in vitro and heat-
evoked firing of spinal dorsal horn neurons in vivo. J. Pharmacol.
Exp. Ther. 2008, 326, 879–888.
(29) Cheng, C.-C.; Yan, S.-J. The Friedlander synthesis of quinolines.
Org. React. 1982, 28.
(30) Atkinson, C. M.; Simpson, J. C. E.; Cinnolines., X. The prepara-
tion of 4-chloro-2-aminoacetophenone and related 4-hydroxycin-
nolines. J. Chem. Soc. 1947, 232–237.
(31) Compounds were tested as previously described: Szallasi, A.;
Blumberg, P. M.; Annicelli, L. L.; Krause, J. E.; Cortright, D. N.
The cloned rat vanilloid receptor VR1 mediates both R-type
binding and C-type calcium response in dorsal root ganglion
neurons. Mol. Pharmacol. 1999, 56, 581–587.
(18) Zheng., X.; Hodgetts, K. J.; Brielmann, H.; Hutchison, A.;Burkamp,
F.; Jones, A. B.; Blurton, P.; Clarkson, R.; Chandrasekhar, J.;
Bakthavatchalam, R.; De Lombaert, S.; Crandall, M.; Cortright,